/TCDA
TCDA Stock - Tricida, Inc.
Healthcare|BiotechnologyNASDAQ
$0.11+0.00%
+$0.00 (+0.00%) • Jan 23
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.80
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+17492.6%upside
Target: $19.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TCDA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.11 – $0.11
TARGET (TP)$19.00
STOP LOSS$0.10
RISK/REWARD1:2361.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.00
52W High$13.85
52W Low$0.04
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-158,964,000 | $-251,400,000 | $-178,824,000 | $-103,595,000 | $-47,122,000 |
| Net Income | $-194,168,000 | $-264,791,000 | $-176,813,000 | $-102,808,000 | $-41,290,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.88 | $-5.29 | $-3.72 | $-4.64 | $-7.53 |
Company Overview
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$25
Average Target
↑ 23048.1% Upside
Now
$25
Low
$25
Average
$25
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 13th 2022 | Goldman | Initiation | Buy | $25 |
Earnings History & Surprises
TCDABeat Rate
65%
Last 17 quarters
Avg Surprise
+6.7%
EPS vs Estimate
Beats / Misses
11/5
1 met exactly
Latest EPS
$-0.44
Q4 2022
EPS Surprise History
Q1 21
+2.7%
$-1.09vs$-1.12
Q2 21
-2.9%
$-1.06vs$-1.03
Q3 21
+20.2%
$-0.67vs$-0.84
Q4 21
-23.4%
$-0.79vs$-0.64
Q4 21
No data
Q2 22
+27.1%
$-0.51vs$-0.70
Q3 22
+15.5%
$-0.49vs$-0.58
Q4 22
+18.5%
$-0.44vs$-0.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2023 | Mar 27, 2023 | $-0.54 | — | — | — |
Q4 2022 | Nov 14, 2022 | $-0.54 | $-0.44 | +18.5% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.58 | $-0.49 | +15.5% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.70 | $-0.51 | +27.1% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-1.00 | — | — |
Q4 2021 | Nov 8, 2021 | $-0.64 | $-0.79 | -23.4% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.84 | $-0.67 | +20.2% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-1.03 | $-1.06 | -2.9% | ✗ MISS |
Q1 2021 | Feb 25, 2021 | $-1.12 | $-1.09 | +2.7% | ✓ BEAT |
Q4 2020 | Nov 9, 2020 | $-1.22 | $-1.55 | -27.0% | ✗ MISS |
Q3 2020 | Aug 5, 2020 | $-1.46 | $-1.16 | +20.5% | ✓ BEAT |
Q2 2020 | May 7, 2020 | $-1.40 | $-1.49 | -6.4% | ✗ MISS |
Q1 2020 | Feb 27, 2020 | $-1.21 | $-1.17 | +3.3% | ✓ BEAT |
Q4 2019 | Nov 14, 2019 | $-0.89 | $-0.89 | 0.0% | = MET |
Q3 2019 | Aug 8, 2019 | $-0.84 | $-0.75 | +10.7% | ✓ BEAT |
Q2 2019 | May 8, 2019 | $-0.77 | $-0.90 | -16.9% | ✗ MISS |
Q1 2019 | Mar 28, 2019 | $-0.89 | $-0.66 | +25.8% | ✓ BEAT |
Q4 2018 | Nov 8, 2018 | $-0.84 | $-0.71 | +15.5% | ✓ BEAT |
Q3 2018 | Aug 8, 2018 | $-0.87 | $-0.60 | +31.0% | ✓ BEAT |
Q1 2018 | Mar 31, 2018 | — | $-2.87 | — | — |
Latest News
Loading news...
Frequently Asked Questions about TCDA
What is TCDA's current stock price?
Tricida, Inc. (TCDA) is currently trading at $0.11 per share. The stock has moved +0.00% today.
What is the analyst price target for TCDA?
The average analyst price target for TCDA is $19.00, based on 1 analyst.
What sector is Tricida, Inc. in?
Tricida, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TCDA's market cap?
Tricida, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does TCDA pay dividends?
No, Tricida, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPTO
Aptose Biosciences Inc.
$1.71
Mkt Cap: $0.0B
BVXV
BiondVax Pharmaceuticals Ltd.
$1.36
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
FRTX
Fresh Tracks Therapeutics, Inc.
$0.94
Mkt Cap: $0.0B
GMDA
Gamida Cell Ltd.
$0.03
Mkt Cap: $0.0B
MODV
ModivCare Inc.
$0.43
Mkt Cap: $0.0B
NEUP
Neuphoria Therapeutics Inc.
$3.89
Mkt Cap: $0.0B
TECX
Tectonic Therapeutic, Inc.
$19.56
Mkt Cap: $0.4B
XAGE
Longevity Health Holdings Inc.
$0.43
Mkt Cap: $0.0B
XBIO
Xenetic Biosciences, Inc.
$2.15
Mkt Cap: $0.0B
Explore stocks similar to TCDA for comparison